Jian Zhou

Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma

Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

Contemporaneous and temporal symptom drivers during breast cancer chemotherapy: A prospective repeated-measures cohort study

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation

CD177 ⁺ neutrophils drive extracellular matrix remodelling and HGF-alpha release in ALPPS-induced liver regeneration

FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial.

Demoralization and dignity loss in breast cancer: A network analysis and computer simulation study

Neutrophil profiling illuminates anti-tumor antigen-presenting potency

A blueprint for tumor-infiltrating B cells across human cancers

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming

Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma

ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis

RECQL4 Inhibits Radiation‐Induced Tumor Immune Awakening via Suppressing the cGAS‐STING Pathway in Hepatocellular Carcinoma

Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation

Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma

A <scp>Transformer‐Based</scp> microvascular invasion classifier enhances prognostic stratification in <scp>HCC</scp> following radiofrequency ablation

Prolonged Survival of Neutrophils Induced by Tumor‐Derived G‐CSF/GM‐CSF Promotes Immunosuppression and Progression in Laryngeal Squamous Cell Carcinoma

Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver

CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma

Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution

Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor

An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte–tumor cell crosstalk, local immunosuppression and tumor progression

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights